AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. 詳細を表示
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.8 | -3.63636363636 | 22 | 22.95 | 20.81 | 509629 | 21.81436663 | CS |
4 | -12.53 | -37.1479395197 | 33.73 | 36.54 | 19 | 568228 | 24.89907086 | CS |
12 | -15.16 | -41.6941694169 | 36.36 | 40.7 | 19 | 375156 | 30.16502651 | CS |
26 | -2.26 | -9.63341858483 | 23.46 | 41.3083 | 19 | 356740 | 29.48916453 | CS |
52 | 6.93 | 48.5634197617 | 14.27 | 41.3083 | 13.36 | 335870 | 25.98664331 | CS |
156 | -11.54 | -35.2474037874 | 32.74 | 41.3083 | 13.36 | 276808 | 24.60391583 | CS |
260 | 10.52 | 98.5018726592 | 10.68 | 41.3083 | 10.45 | 315916 | 22.4094509 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約